RESUMO
4-Nitroso-3-trifluoromethyl-5-alkyl[(het)aryl]pyrazoles were synthesized via one-pot nitrosation of 1,3-diketones or their lithium salts followed by treatment of hydrazines. Reduction of nitroso-derivatives made it possible to obtain 4-amino-3-trifluoromethylpyrazoles chlorides. According to computer-aided calculations, all synthesized compounds are expected to have acceptable ADME profile for drug design. Tuberculostatic, antibacterial, antimycotic, antioxidant and cytotoxic activities of the compounds were evaluated in vitro, while their analgesic and anti-inflammatory action was tested in vivo along with acute toxicity studies. N-Unsubstituted 4-nitrosopyrazoles were the most effective tuberculostatics (MIC to 0.36 µg/ml) and antibacterial agents against Streptococcus pyogenes (MIC to 7.8 µg/ml), Staphylococcus aureus,S. aureus MRSA and Neisseria gonorrhoeae (MIC to 15.6 µg/ml). 4-Nitroso-1-methyl-5-phenylpyrazole had the pronounced antimycotic action against a wide range of fungi (Trichophytonrubrum, T. tonsurans, T. violaceum, T. interdigitale, Epidermophytonfloccosum, Microsporumcanis with MIC 0.38-12.5 µg/ml). N-Unsubstituted 4-aminopyrazoles shown high radical-scavenging activity in ABTS test, ORAC/AAPH and oxidative erythrocyte hemolysis assays. 1-Methyl-5-phenyl-3-trifluoromethylpyrazol-4-aminium chloride revealed potential anticancer activity against HeLa cells (SI > 1351). The pronounced analgesic activity was found for 4-nitroso- and 4-aminopyrazoles having phenyl fragment at the position 5 in "hot plate" test. The most of the obtained pyrazoles had a moderate acute toxicity.
Assuntos
Compostos Nitrosos/farmacologia , Pirazóis/farmacologia , Animais , Bactérias/efeitos dos fármacos , Ensaios de Seleção de Medicamentos Antitumorais , Epidermophyton/efeitos dos fármacos , Células HeLa , Humanos , Camundongos , Testes de Sensibilidade Microbiana , Estrutura Molecular , Compostos Nitrosos/síntese química , Compostos Nitrosos/farmacocinética , Compostos Nitrosos/toxicidade , Pirazóis/síntese química , Pirazóis/farmacocinética , Pirazóis/toxicidade , Ratos Sprague-Dawley , Relação Estrutura-Atividade , Trichophyton/efeitos dos fármacosRESUMO
Diet is associated with the development of cancer in the gastrointestinal (GI) tract, because dietary nitrate and nitrite are the main nitrosating agents that are responsible for the formation of carcinogenic N-nitroso compounds (NOCs) when nitrosatable substrates, such as amine and amide, are present in the GI tract. However, whether the nitroso compounds become beneficial S-nitroso compounds or carcinogenic NOCs might depend on dietary and environmental factors including food stuffs, gastric acidity, microbial flora, and the mean transit time of digesta. This review focused on GI NOC formation and environmental risk factors affecting its formation to provide appropriate nutritional strategies to prevent the development of GI cancer.
Assuntos
Neoplasias Colorretais/etiologia , Dieta , Doenças Inflamatórias Intestinais/etiologia , Nitratos/farmacocinética , Compostos Nitrosos/metabolismo , Colo/microbiologia , Disbiose/etiologia , Esôfago/metabolismo , Humanos , Óxido Nítrico/metabolismo , Nitritos/farmacocinética , Compostos Nitrosos/efeitos adversos , Compostos Nitrosos/farmacocinética , Estômago/efeitos dos fármacosRESUMO
In the latest trend of anticancer chemotherapy research, there were many macromolecular anticancer drugs developed based on enhanced permeability and retention (EPR) effect, such as albumin bound paclitaxel nanoparticle (nab- PTX, also called Abraxane®). However, cancers with low vascular permeability posed a challenge for these EPR based therapeutic systems. Augmenting the intrinsic EPR effect with an intrinsic vascular modulator such as nitric oxide (NO) could be a promising strategy. S-nitrosated human serum albumin dimer (SNO-HSA Dimer) shown promising activity previously was evaluated for the synergistic effect when used as a pretreatment agent in nab-PTX therapy against various tumor models. In the high vascular permeability C26 murine colon cancer subcutaneous inoculation model, SNO-HSA Dimer enhanced tumor selectivity of nab-PTX, and attenuated myelosuppression. SNO-HSA Dimer also augmented the tumor growth inhibition of nab-PTX in low vascular permeability B16 murine melanoma subcutaneous inoculation model. Furthermore, nab-PTX therapy combined with SNO-HSA Dimer showed higher antitumor activity and improved survival rate of SUIT2 human pancreatic cancer orthotopic model. In conclusion, SNO-HSA Dimer could enhance the therapeutic effect of nab-PTX even in low vascular permeability or intractable pancreatic cancers. The possible underlying mechanisms of action of SNO-HSA Dimer were discussed.
Assuntos
Paclitaxel Ligado a Albumina/uso terapêutico , Antineoplásicos/uso terapêutico , Neoplasias/tratamento farmacológico , Compostos Nitrosos/uso terapêutico , Albumina Sérica Humana/uso terapêutico , Paclitaxel Ligado a Albumina/farmacocinética , Paclitaxel Ligado a Albumina/farmacologia , Albuminas/farmacocinética , Albuminas/farmacologia , Albuminas/uso terapêutico , Animais , Antineoplásicos/farmacocinética , Antineoplásicos/farmacologia , Permeabilidade Capilar/efeitos dos fármacos , Linhagem Celular Tumoral , Sinergismo Farmacológico , Feminino , Humanos , Masculino , Melanoma Experimental/tratamento farmacológico , Melanoma Experimental/metabolismo , Melanoma Experimental/patologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Neoplasias/metabolismo , Neoplasias/patologia , Óxido Nítrico/metabolismo , Compostos Nitrosos/farmacocinética , Compostos Nitrosos/farmacologia , Paclitaxel/farmacocinética , Paclitaxel/farmacologia , Paclitaxel/uso terapêutico , Neoplasias Pancreáticas/tratamento farmacológico , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/patologia , Multimerização Proteica , Albumina Sérica Humana/farmacocinética , Albumina Sérica Humana/farmacologiaRESUMO
Macromolecules have been developed as carriers of low-molecular-weight drugs in drug delivery systems (DDS) to improve their pharmacokinetic profile or to promote their uptake in tumor tissue via enhanced permeability and retention (EPR) effects. We have previously demonstrated that poly-nitric oxide (NO) conjugated human serum albumin (Poly-SNO-HSA) has the potential to be a DDS carrier capable of accumulating NO in tumors. However, the stability of Poly-SNO-HSA in the circulation has to be improved, and its optimal molecular size for using the EPR effects has to be evaluated. In the present study, we performed two tuning methods for refining Poly-SNO-HSA, namely, pegylation and dimerization. We observed that pegylation enhanced the stability of Poly-SNO-HSA both in vitro and in vivo, and that dimerization of Poly-SNO-HSA enhanced the antitumor activity via more efficient delivery of NO in Colon 26 tumor-bearing mice. Intriguingly, dimerization resulted in a 10 times higher antitumor activity. These data suggest that pegylation and dimerization of Poly-SNO-HSA are very important tuners to optimize NO stability and accumulation, and thereby effect, in tumors. Thus, polyethylene glycol-Poly-SNO-HSA dimer seems to be a very appealing and safe NO carrier and thereby a strong candidate as an antitumor drug in future development of cancer therapeutics.
Assuntos
Antineoplásicos/química , Portadores de Fármacos/química , Nanomedicina/métodos , Óxido Nítrico/metabolismo , Compostos Nitrosos/química , Polietilenoglicóis/química , Albumina Sérica/química , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/farmacocinética , Antineoplásicos/uso terapêutico , Linhagem Celular Tumoral , Liberação Controlada de Fármacos , Estabilidade de Medicamentos , Humanos , Masculino , Camundongos Endogâmicos , Compostos Nitrosos/administração & dosagem , Compostos Nitrosos/farmacocinética , Compostos Nitrosos/uso terapêutico , Multimerização Proteica , Ratos Endogâmicos , Albumina Sérica/administração & dosagem , Albumina Sérica/farmacocinética , Albumina Sérica/uso terapêutico , Albumina Sérica Humana , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
Nitrite anion is bioactive nitric oxide (NO) species circulating in blood, and represents the NO bioavailability and endothelial function. In this study, we aimed to investigate the nitrite levels and the correlation with hemolysis and severity in ß-thalassemia/hemoglobin E (ß-thal/HbE). 38 Children (12.0±1.9 years of age) with a diagnosis of mild, moderate and severe ß-thalassemia were enrolled in the study. The blood nitrite levels and potential plasma NO consumption were measured by the chemiluminescence method. The nitrite levels in whole blood and erythrocytes of the severe thalassemia subjects were lower than those of the control subjects. At day 7 after transfusion of packed erythrocytes, the nitrite levels in erythrocytes increased. The plasma hemoglobin and NO consumption increased in the severe thalassemia subjects. The nitrite levels in erythrocytes inversely correlated with plasma hemoglobin, lactate dehydrogenase activity, potential NO consumption, and lipid peroxidation. Our studies demonstrate the decreased NO bioavailability in thalassemia, which could result from endothelial dysfunction, the increased potential NO consumption in plasma by cell-free hemoglobin and oxidative stress.
Assuntos
Hemoglobina E/metabolismo , Nitritos/sangue , Talassemia beta/sangue , Adolescente , Análise de Variância , Estudos de Casos e Controles , Criança , Eritrócitos , Feminino , Hemoglobinas/metabolismo , Humanos , Masculino , Óxido Nítrico/sangue , Doadores de Óxido Nítrico/administração & dosagem , Doadores de Óxido Nítrico/farmacocinética , Compostos Nitrosos/administração & dosagem , Compostos Nitrosos/farmacocinética , Talassemia beta/tratamento farmacológico , Talassemia beta/metabolismoRESUMO
Nitroxyl (HNO) donors have potential benefit in the treatment of heart failure and other cardiovascular diseases. 1-Nitrosocyclohexyl acetate (NCA), a new HNO donor, in contrast to the classic HNO donors Angeli's salt and isopropylamine NONOate, predominantly releases HNO and has a longer half-life. This study investigated the vasodilatative properties of NCA in isolated aortic rings and human platelets and its mechanism of action. NCA was applied on aortic rings isolated from wild-type mice and apolipoprotein E-deficient mice and in endothelial-denuded aortae. The mechanism of action of HNO was examined by applying NCA in the absence and presence of the HNO scavenger glutathione (GSH) and inhibitors of soluble guanylyl cyclase (sGC), adenylyl cyclase (AC), calcitonin gene-related peptide receptor (CGRP), and K(+) channels. NCA induced a concentration-dependent relaxation (EC(50), 4.4 µM). This response did not differ between all groups, indicating an endothelium-independent relaxation effect. The concentration-response was markedly decreased in the presence of excess GSH; the nitric oxide scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide had no effect. Inhibitors of sGC, CGRP, and voltage-dependent K(+) channels each significantly impaired the vasodilator response to NCA. In contrast, inhibitors of AC, ATP-sensitive K(+) channels, or high-conductance Ca(2+)-activated K(+) channels did not change the effects of NCA. NCA significantly reduced contractile response and platelet aggregation mediated by the thromboxane A(2) mimetic 9,11-dideoxy-11α,9α-epoxymethanoprostaglandin F(2)(α) in a cGMP-dependent manner. In summary, NCA shows vasoprotective effects and may have a promising profile as a therapeutic agent in vascular dysfunction, warranting further evaluation.
Assuntos
Acetatos/farmacologia , Doadores de Óxido Nítrico/farmacologia , Óxidos de Nitrogênio/metabolismo , Compostos Nitrosos/farmacologia , Inibidores da Agregação Plaquetária/farmacologia , Vasodilatação/efeitos dos fármacos , Vasodilatadores/farmacologia , Acetatos/farmacocinética , Animais , Aorta Torácica/efeitos dos fármacos , Aorta Torácica/metabolismo , Apolipoproteínas E/deficiência , Aterosclerose/metabolismo , Aterosclerose/fisiopatologia , Aterosclerose/prevenção & controle , Plaquetas/citologia , Plaquetas/efeitos dos fármacos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/metabolismo , Endotélio Vascular/fisiologia , Meia-Vida , Humanos , Técnicas In Vitro , Camundongos , Camundongos Endogâmicos C57BL , Doadores de Óxido Nítrico/farmacocinética , Compostos Nitrosos/farmacocinética , Agregação Plaquetária/efeitos dos fármacos , Inibidores da Agregação Plaquetária/farmacocinética , Vasodilatadores/farmacocinéticaRESUMO
BACKGROUND/AIM: Nitrosylcobalamin (NO-Cbl) is a cobalamin-based anti-tumor agent. This study evaluated the pharmacokinetic parameters of NO-Cbl following intravenous administration in dogs. MATERIALS AND METHODS: Four dogs received 10 mg/kg, 20 mg/kg and 40 mg/kg intravenous bolus doses of NO-Cbl, with a 14-day washout period between doses. Blood samples were collected at baseline and post-dosing, and noncompartmental pharmacokinetic parameters were determined. RESULTS: Average peak serum concentrations of 2265, 5523 and 13,866 pg/mL were achieved following single-dose bolus intravenous administration of 10 mg/kg, 20 mg/kg and 40 mg/kg of NO-Cbl respectively. The average area under the curve was 12,697 h × pg/mL, 24,497 h × pg/mL and 44,976 h × pg/mL respectively, with an average elimination half-life of 16.2 h, 13.5 h and 13.1 h respectively. CONCLUSION: These results can be used to determine the dose and dosing intervals for clinical trials evaluating NO-Cbl in humans and companion animals.
Assuntos
Antineoplásicos/farmacocinética , Compostos Nitrosos/farmacocinética , Vitamina B 12/análogos & derivados , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/sangue , Cães , Injeções Intravenosas , Masculino , Compostos Nitrosos/administração & dosagem , Compostos Nitrosos/sangue , Projetos Piloto , Vitamina B 12/administração & dosagem , Vitamina B 12/sangue , Vitamina B 12/farmacocinéticaRESUMO
Several studies have implicated the role of Nitric Oxide (NO) in the regulation of tumor cell behavior and have shown that NO either promotes or inhibits tumorigenesis. These conflicting findings have been resolved, in part, by the levels of NO used such that low levels promote tumor growth and high levels inhibit tumor growth. Our studies have focused on the use of high levels of NO provided primarily by the NO donor, DETANONOate. We have shown that treatment of resistant tumor cells with DETANONOate sensitizes them to apoptosis by both chemotherapeutic drugs and cytotoxic immunotherapeutic ligands. The underlying mechanisms by which NO sensitizes tumor cells to apoptosis were shown to be regulated, in part, by NO-mediated inhibition of the NF-κB survival/anti-apoptotic pathways and downstream of NF-κB by inhibition of the transcription factor Yin Yang 1 (YY1). In addition to NO-induced sensitization to apoptosis, we have also shown that NO induced the expression of the metastasis-suppressor/immunosurveillance cancer gene product, Raf-1 kinase inhibitor protein (RKIP). Overexpression of RKIP mimics NO in tumor cells-induced sensitization to apoptosis. The induction of RKIP by NO was the result of the inhibition of the RKIP repressor, Snail, downstream of NF-κB. These findings established the presence of a dysregulated NF-κB/Snail/YY1/ RKIP circuitry in resistance and that treatment with NO modifies this loop in tumor cells in favor of the inhibition of tumor cell survival and the response to cytotoxic drugs. Noteworthy, the NF-κB/Snail/YY1/RKIP loop consists of gene products that regulate the epithelial to mesenchymal transition (EMT) and, thus, tumor metastasis. Hence, we have found that treatment of metastatic cancer cell lines with DETANONOate inhibited the EMT phenotype, through both the inhibition of the metastasis-inducers, NF-κB and Snail and the induction of the metastasis-suppressor, RKIP. Altogether, the above findings establish, for the first time, the dual role of high levels of NO in the sensitization of tumor cells to apoptotic stimuli as well as inhibition of EMT. Hence, NO donors may be considered as novel potential therapeutic agents with dual roles in the treatment of patients with refractory cancer and in the prevention of the initiation of the metastatic cascade via EMT.
Assuntos
Neoplasias/tratamento farmacológico , Doadores de Óxido Nítrico/farmacologia , Compostos Nitrosos/farmacologia , Animais , Transformação Celular Neoplásica , Resistencia a Medicamentos Antineoplásicos , Sinergismo Farmacológico , Humanos , NF-kappa B/metabolismo , Neoplasias/metabolismo , Doadores de Óxido Nítrico/farmacocinética , Compostos Nitrosos/farmacocinética , Proteína de Ligação a Fosfatidiletanolamina/metabolismo , Transdução de Sinais/efeitos dos fármacos , Fatores de Transcrição da Família Snail , Fatores de Transcrição/metabolismo , Fator de Transcrição YY1/metabolismoRESUMO
PURPOSE: Given the limited options available to treat canine cancers, the use of companion animals for evaluating new drugs may identify better therapies for veterinary and human oncology. The anti-tumor effects of nitrosylcobalamin (NO-Cbl), an apoptosis-inducing, vitamin B12-based carrier of nitric oxide (NO), was evaluated in four dogs with spontaneous cancer. EXPERIMENTAL DESIGN: (1) A 13 year-old female spayed Giant Schnauzer with inoperable thyroid carcinoma and hypercalcemia. (2) A 6 year-old male neutered Golden Retriever with a malignant peripheral nerve sheath tumor (MPNST). (3) A ten yr-old neutered male Bichon Frise with apocrine gland anal sac adenocarcinoma (AGACA). (4) A 7 year-old female spayed Labrador mix with spinal meningioma following partial surgical resection. Tumor regression was measured by physical exam and verified using ultrasound (case 1) and MRI (case 2-4). Serum chemistries and hematologic parameters were monitored throughout the studies. RESULTS: (1) The Giant Schnauzer demonstrated a 77% reduction in tumor volume after ten weeks of daily NO-Cbl treatment. (2) The Golden Retriever demonstrated a 53% reduction in tumor volume after 15 months of daily NO-Cbl therapy. (3) The Bichon Frise demonstrated a 43% regression of the primary tumor and a 90% regression of an iliac lymph node measured by MRI after 15 months of treatment. After 61 months, the dog currently has stable disease, normal liver enzymes, CBC analysis, and no evidence of toxicity. (4) The Labrador demonstrated complete regression of the residual tumor after 6 months of treatment. CONCLUSION: We have shown previously that NO-Cbl is endocytosed by malignant cells, resulting in intra-tumoral NO release. In this study, we have shown that daily long-term use of NO-Cbl induced responses in all dogs without any signs of toxicity. The use of NO-Cbl capitalizes on the tumor-specific properties of the vitamin B12 receptor and represents a promising anti-cancer therapy.
Assuntos
Doenças do Cão/tratamento farmacológico , Neoplasias/veterinária , Compostos Nitrosos/uso terapêutico , Vitamina B 12/análogos & derivados , Animais , Antineoplásicos/metabolismo , Antineoplásicos/farmacocinética , Antineoplásicos/uso terapêutico , Doenças do Cão/diagnóstico por imagem , Doenças do Cão/patologia , Cães , Relação Dose-Resposta a Droga , Feminino , Imageamento por Ressonância Magnética , Masculino , Neoplasias/diagnóstico por imagem , Neoplasias/tratamento farmacológico , Neoplasias/patologia , Compostos Nitrosos/metabolismo , Compostos Nitrosos/farmacocinética , Carga Tumoral , Ultrassonografia , Vitamina B 12/metabolismo , Vitamina B 12/farmacocinética , Vitamina B 12/uso terapêuticoRESUMO
In the year 1992, S-nitrosoalbumin (SNALB) has been proposed to be the most abundant physiological carrier and pool of nitric oxide (NO) activity in human circulation, by which NO-dependent biological functions are regulated. The concentration, the metabolism and the mechanisms of the biological actions of SNALB are controversial and still incompletely understood. Moreover, the suitability of SNALB as a biomarker of diseases associated with altered NO bioactivity in human circulation has not been demonstrated convincingly so far. In the present study, we report on the development and application of a stable-isotope technique to study the pharmacokinetics of (15)N-labelled SNALB (S(15)NALB) in anesthetized rats. S(15)NALB was synthesized from albumin isolated by affinity chromatography from freshly prepared human plasma. This technique was also applied to study and quantify the formation of S(15)NALB from endogenous rat plasma albumin and intravenously applied S-[(15)N]nitrosoglutathione (GS(15)NO) or S-[(15)N]nitrosocysteine (S(15)NC) in anesthetized rats. In these investigations the mean arterial pressure (MAP) was monitored continuously. The elimination half-life (t(1/2)) of S(15)NALB from rat plasma was determined to be 4.1 min (t(1/2)alpha) and 9.4 min (t(1/2)beta). S(15)NALB (125 nmol) produced long-lasting decreases in MAP (by 49% for 18 min). Thirty minutes after intravenous (i.v.) injection of S(15)NALB (125 nmol), repeated i.v. injection of L-cysteine or D-cysteine (10 micromol each) produced repeatedly potent (by 44-55%) but short-lasting (about 4 min) MAP falls. Intravenously administered GS(15)NO and S(15)NC (each 500 nmol) could not be isolated from rat blood. (15)N-Labelled nitrite and nitrate were identified as the major metabolites of all investigated S-nitrosothiols in rat plasma. The results of this study suggest that in the rat S(15)NALB is a potent S-transnitrosylating agent and that the blood pressure-lowering effect of S(15)NALB and other S-nitrosothiols are mediated largely by L-cysteine via S-transnitrosylation to form S(15)NC that subsequently releases (15)NO. Our results also suggest that S-transnitrosylation of the single reduced cysteine moiety of albumin by endogenous GSNO or SNC in blood is possible but does not represent an effective mechanism to produce SNALB in vivo. This stable-isotope dilution GC-MS technique is suitable to perform in vivo studies on SNALB using physiologically and pharmacologically relevant doses.
Assuntos
Compostos Nitrosos/farmacocinética , Soroalbumina Bovina/farmacocinética , Animais , Cromatografia de Afinidade , Cromatografia Gasosa-Espectrometria de Massas , Meia-Vida , Humanos , Masculino , Isótopos de Nitrogênio , Compostos Nitrosos/sangue , Agregação Plaquetária , Ratos , Ratos Sprague-Dawley , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
The uptake and fate of the emerging contaminants N-nitrosodimethylamine (NDMA) and perchlorate in phreatophytes was studied in a hydroponics system under greenhouse conditions. NDMA is a potent carcinogen, and perchlorate disrupts the functioning ofthe human thyroid gland. The rate of removal of NDMA from solution by rooted cuttings of black willow (Salix nigra) and hybrid poplar (Populus deltoides x nigra, DN34) trees varied seasonally, with faster removal in summer months when transpiration rates were highest. A linear correlation between the volume of water transpired and mass of NDMA removed from the root zone was observed, especially at higher NDMA concentrations. In bioreactors dosed with both NDMA (0.7-1.0 mg L(-1)) and perchlorate (27 mg L(-1)), no competitive uptake of NDMA and perchlorate was observed. While NDMA was primarily removed from solution by plant uptake, perchlorate was predominantly removed by rhizodegradation. In the presence of NDMA, a slower rate of rhizodegradation of perchlorate was observed, but still significantly faster than the rate of NDMA uptake. For experiments conducted with radiolabeled NDMA, 46.4 +/- 1.1% of the total 14C-activity was recovered in the plant tissues and 47.5% was phytovolatilized. The 46.4 +/- 1.1% recovered in the plants was distributed as follows: 18.8 +/- 1.4% in leaves, 15.9 +/- 5.9% in stems, 7.6 +/- 3.2% in branches, and 3.5 +/- 3.3% in roots. The poor extractability of NDMA with methanol-water (1:1 v/v) from stem and leaf tissues suggested that some fraction of NDMA was assimilated. The calculated transpiration stream concentration factor (TSCF) of 0.28 +/- 0.06 suggests that NDMA is passively taken up by phreatophytes, and mainly phytovolatilized.
Assuntos
Compostos Nitrosos/farmacocinética , Percloratos/farmacocinética , Raízes de Plantas/metabolismo , Populus/metabolismo , Salix/metabolismo , Poluentes Químicos da Água/análise , Purificação da Água/métodos , Biodegradação Ambiental , Radioisótopos de Carbono , Cromatografia Gasosa , Cromatografia em Camada Fina , Hidroponia , Compostos Nitrosos/metabolismo , Percloratos/metabolismo , Transpiração Vegetal/fisiologia , Populus/fisiologia , Salix/fisiologiaRESUMO
Beta-catenin plays an important role in colonic tumorigenesis whereas inducible nitric oxide synthase and nitric oxide are elevated in colonic inflammation. Resistance of colonic epithelial cells to the induction of apoptosis may contribute to tumor development. Nitric oxide can stimulate apoptosis and, paradoxically, is implicated in the development of colon cancer. Our hypothesis was that beta-catenin could increase the resistance of colonic cancer cells to nitric oxide-induced apoptotic cell death. Here we show, using a beta-catenin overexpression system, that increased cytosolic beta-catenin renders colonic epithelial cells more resistant to nitric oxide-induced apoptotic cell death, independently of nitric oxide-induced accumulation of p53. Furthermore, we show that this occurs through inhibition of nitric oxide-induced release of cytochrome c from mitochondria and by blocking both the nitric oxide-induced suppression of the antiapoptotic protein, Bcl-xL, and the phosphorylation of Akt. We contend that increased nitric oxide production, such as that which occurs in chronic colonic inflammation, may select the cells with oncogenic mutant beta-catenin regulatory genes and contribute to human colonic carcinogenesis and tumor progression.
Assuntos
Apoptose/fisiologia , Neoplasias do Colo/metabolismo , Neoplasias do Colo/patologia , Óxido Nítrico/antagonistas & inibidores , beta Catenina/biossíntese , Apoptose/efeitos dos fármacos , Linhagem Celular Tumoral , Neoplasias do Colo/genética , Humanos , Óxido Nítrico/farmacocinética , Óxido Nítrico/farmacologia , Doadores de Óxido Nítrico/farmacocinética , Doadores de Óxido Nítrico/farmacologia , Compostos Nitrosos/antagonistas & inibidores , Compostos Nitrosos/farmacocinética , Compostos Nitrosos/farmacologia , Proteínas Proto-Oncogênicas c-akt/metabolismo , Transfecção , Proteína Supressora de Tumor p53/metabolismo , Proteína bcl-X/metabolismo , beta Catenina/genéticaRESUMO
Sulfamethoxazole hypersensitivity may be caused by production of the protein-reactive metabolite nitroso sulfamethoxazole (SMX-NO) and interaction of SMX-NO with T-cells. We have characterised the nature of the immune response induced by administration of sulfamethoxazole, sulfamethoxazole metabolites and nitrosobenzene to BALB/c mice. Drugs were administered over a 13-day period to induce polarised cytokine secretion profiles. Proliferation was measured by [(3)H] thymidine incorporation. Cytokine secretion was monitored by ELISA. Results were compared with those provoked by exposure to type 1 and type 2 chemical allergens, 2,4-dinitrochlorobenzene (DNCB) and trimellitic anhydride (TMA). CD4(+) or CD8(+) T-cells were depleted ex vivo to identify the primary source of cytokines. Lymph node activation was observed following treatment with DNCB, TMA, nitrosobenzene and SMX-NO, but not with sulfamethoxazole or sulfamethoxazole hydroxylamine (SMX-NHOH). DNCB and TMA induced type 1 and type 2 cytokine profiles, respectively. SMX-NO treatment stimulated the production of high levels of IL-5, variable amounts of IFN-gamma, and relatively low levels of IL-10 and IL-4. Nitrosobenzene-activated lymph node cells secreted only low levels of IFN-gamma and IL-5. Depletion of CD4(+) or CD8(+) T-cells from SMX-NO stimulated lymph node cells revealed that CD4(+) T-cells were the major source of IL-5. In conclusion, the data presented indicates that subcutaneous administration to mice of SMX-NO, but not the parent drug, stimulated the secretion of high levels of IL-5 from activated CD4(+) T-cells, which is consistent with the clinical profile of the drug.
Assuntos
Anti-Infecciosos/imunologia , Linfócitos T CD4-Positivos/efeitos dos fármacos , Linfócitos T CD4-Positivos/imunologia , Hipersensibilidade a Drogas/etiologia , Interleucina-5/biossíntese , Compostos Nitrosos/toxicidade , Sulfametoxazol/análogos & derivados , Sulfametoxazol/toxicidade , Animais , Anti-Infecciosos/farmacocinética , Linfócitos T CD4-Positivos/citologia , Linfócitos T CD8-Positivos/citologia , Linfócitos T CD8-Positivos/imunologia , Citocinas/biossíntese , Citocinas/imunologia , Dinitroclorobenzeno/imunologia , Hipersensibilidade a Drogas/imunologia , Ensaio de Imunoadsorção Enzimática , Feminino , Interleucina-5/imunologia , Ativação Linfocitária/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos BALB C , Compostos Nitrosos/imunologia , Compostos Nitrosos/farmacocinética , Anidridos Ftálicos/imunologia , Sulfametoxazol/imunologia , Sulfametoxazol/metabolismo , Sulfametoxazol/farmacocinética , Células Th1/imunologia , Células Th2/imunologiaRESUMO
The N-nitroso-derivative of melatonin, NOM (1-nitrosomelatonin), which has been demonstrated to be a NO* [oxidonitrogen*] donor in buffered solutions, is a new potential drug particularly in neurological diseases. The advantage of NOM, a very lipophilic drug, is its ability to release both melatonin and NO*, an easily diffusible free radical. In order to evaluate the distribution and the pharmacokinetics of NOM, [O-methyl-3H]NOM was administered to and followed in mice. A complementary method for monitoring NOM, EPR, was performed in vitro and ex vivo with (MGD)2-Fe2+ (iron-N-methyl-D-glucamine dithiocarbamate) complex as a spin trap. The behaviour of NOM was compared with that of GSNO (S-nitrosoglutathione), a hydrophilic NO* donor. In the first minutes following [O-methyl-3H]NOM intraperitoneal injection, the radioactivity was found in organs (6% in the liver, 1% in the kidney and 0.6% in the brain), but not in the blood. In both liver and brain, the radioactivity content decreased over time with similar kinetics reflecting the diffusion and metabolism of NOM and of its metabolites. Based on the characterization and the quantification of the EPR signal in vitro with NOM or GSNO using (MGD)2-Fe2+ complex in phosphate-buffered solutions, the detection of these nitroso compounds was realized ex vivo in mouse tissue extracts. (MGD)2-Fe2+-NO was observed in the brain of NOM-treated mice in the first 10 min following injection, revealing that NOM was able to cross the blood-brain barrier, while GSNO was not.
Assuntos
Melatonina/análogos & derivados , Compostos Nitrosos/farmacocinética , S-Nitrosoglutationa/farmacocinética , Animais , Barreira Hematoencefálica , Encéfalo/metabolismo , Espectroscopia de Ressonância de Spin Eletrônica , Feminino , Fígado/metabolismo , Melatonina/farmacocinética , Camundongos , Camundongos Endogâmicos C57BL , Sorbitol/análogos & derivados , Marcadores de Spin , Tiocarbamatos , Distribuição Tecidual , TrítioRESUMO
Metallothionein (MT) is a two-domain protein with zinc thiolate clusters that bind and release zinc depending on the redox states of the sulfur ligands. Since S-nitrosylation of cysteine is considered a prototypic cellular redox signaling mechanism, we here investigate the reactions of S-nitrosothiols with different isoforms of MT. MT-III is significantly more reactive than MT-I/II toward S-nitrosothiols, whereas the reactivity of all three isoforms toward reactive oxygen species is comparable. A cellular system, in which all three MTs are similarly effective in protecting rat embryonic cortical neurons in primary culture against hydrogen peroxide but where MT-III has a much more pronounced effect of protecting against S-nitrosothiols, confirms this finding. MT-III is the only isoform with consensus acid-base sequence motifs for S-nitrosylation in both domains. Studies with synthetic and zinc-reconstituted domain peptides demonstrate that S-nitrosothiols indeed release zinc from both the alpha- and the beta-domain of MT-III. S-Nitrosylation occurs via transnitrosation, a mechanism that differs fundamentally from that of previous studies of reactions of MT with NO*. Our data demonstrate that zinc thiolate bonds are targets of S-nitrosothiol signaling and further indicate that MT-III is biologically specific in converting NO signals to zinc signals. This could bear importantly on the physiological action of MT-III, whose biological activity as a neuronal growth inhibitory factor is unique, and for brain diseases that have been related to oxidative or nitrosative stress.
Assuntos
Metalotioneína/metabolismo , Proteínas do Tecido Nervoso/metabolismo , Compostos Nitrosos/farmacocinética , Compostos de Sulfidrila/farmacocinética , Zinco/metabolismo , Sequência de Aminoácidos , Animais , Sítios de Ligação , Humanos , Peróxido de Hidrogênio/farmacocinética , Cinética , Metalotioneína 3 , Dados de Sequência Molecular , Proteínas do Tecido Nervoso/química , Neurônios/efeitos dos fármacos , Neurônios/fisiologia , Neurotoxinas/toxicidade , Compostos Nitrosos/farmacologia , Coelhos , Alinhamento de Sequência , Homologia de Sequência de Aminoácidos , Compostos de Sulfidrila/farmacologiaRESUMO
High amounts of nitric oxide (NO) produced by activated macrophages or NO donors are required to induce cytotoxicity and apoptosis in pathogens and tumor cells. High concentrations of NO may lead to nonspecific toxicity thereby limiting the use of NO donors in the treatment of cancer. In this study, we tested the possibility of potentiating the apoptotic action of NO in a human breast cancer cell line, MDA-MB-468, by combining it with a farnesyltransferase inhibitor (FTI), which has been shown to induce apoptosis in some other cancer cell lines with minimal toxicity to normal cells. DETA-NONOate, a long acting NO donor which has a half-life of 20 h at 37 degrees C, was used in this study. DETA-NONOate (1 mM), which releases NO in the range produced by activated macrophages, induced apoptosis after 36 h in MDA-MB-468 cells via cytochrome c release and caspase-9 and -3 activation. FTI (25 microM) potentiated the action of lower concentrations of DETA-NONOate (25-100 microM) by inducing apoptosis in these cells within 24 h by increasing cytochrome c release and caspase-9 and -3 activation. This effect was observed preferentially in the cancer cell lines studied with no apoptosis induction in normal breast epithelial cells. This novel combination of FTI and NO may emerge as a promising approach for the treatment of breast cancer.
Assuntos
Alquil e Aril Transferases/antagonistas & inibidores , Apoptose/efeitos dos fármacos , Neoplasias da Mama/patologia , Óxido Nítrico/farmacologia , Apoptose/fisiologia , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/enzimologia , Sinergismo Farmacológico , Inibidores Enzimáticos/farmacologia , Farnesiltranstransferase , Humanos , Óxido Nítrico/farmacocinética , Doadores de Óxido Nítrico/farmacocinética , Doadores de Óxido Nítrico/farmacologia , Compostos Nitrosos/farmacocinética , Compostos Nitrosos/farmacologia , Células Tumorais CultivadasRESUMO
Nitric oxide (NO) appears in the exhaled breath and is elevated in inflammatory diseases. We developed a steady-state mathematical model of the bronchial mucosa for normal small and large airways to understand NO and S-nitrosoglutathione (GSNO) kinetics and transport using data from the existing literature. Our model predicts that mean steady-state NO and GSNO concentrations for large airways (generation 1) are 2.68 nM and 113 pM, respectively, in the epithelial cells and 0.11 nM (approximately 66 ppb) and 507 nM in the mucus. For small airways (generation 15), the mean concentrations of NO and GSNO, respectively, are 0.26 nM and 21 pM in the epithelial cells and 0.02 nM (approximately 12 ppb) and 132 nM in the mucus. The concentrations in the mucus compare favorably to experimentally measured values. We conclude that 1) the majority of free NO in the mucus, and thus exhaled NO, is due to diffusion of free NO from the epithelial cell and 2) the heterogeneous airway contribution to exhaled NO is due to heterogeneous airway geometries, such as epithelium and mucus thickness.
Assuntos
Brônquios/fisiologia , Glutationa/análogos & derivados , Glutationa/farmacocinética , Modelos Biológicos , Óxido Nítrico/metabolismo , Compostos Nitrosos/farmacocinética , Mucosa Respiratória/fisiologia , Humanos , Cinética , Matemática , Inibidores da Agregação Plaquetária/farmacocinética , Reprodutibilidade dos Testes , S-Nitrosoglutationa , Traqueia/fisiologiaRESUMO
A simple colorimetric flow-injection system for the determination of Cu(II) based on a complexation reaction with nitroso-R salt is described. The chemical and FIA variables were established using the univariate and simplex methods. A small volume of Cu(II) was mixed with merged streams of nitroso-R salt and acetate buffer solutions. The absorbance of the complex was continuously monitored at 492 nm. The calibration curve over the concentration range 1.0-7.0 microg ml(-1) was obtained. The relative standard deviation for determining 4.0 microg ml(-1) Cu(II) was 0.47% (n = 11). The detection limit (3sigma) was 0.68 microg ml(-1) and the sample throughput was 150 h(-1). The validity of the method has been satisfactorily examined for the determination of Cu(II) in wastewater and copper ore samples. The accuracy was found to be high, because the student t-values were calculated to be less than the theoretical values when the results were compared with those obtained by FAAS.
Assuntos
Cobre/análise , Compostos Nitrosos/análise , Espectrofotometria/métodos , Calibragem , Cátions , Cobre/farmacocinética , Concentração de Íons de Hidrogênio , Íons , Compostos Nitrosos/farmacocinética , Sensibilidade e Especificidade , Espectrofotometria/instrumentação , Poluentes Químicos da Água/análiseRESUMO
Because nitric oxide (NO) inhibits the expression of endothelial leukocyte adhesion molecules, NO-generating compounds have major therapeutic potential for use outside their classical indications. We report on the in vitro potential antiatherogenicity of two novel cysteine-containing NO donors, SP/W 3672, a fast spontaneous NO releaser, and its prodrug SP/W 5186, which liberates NO after bioactivation. The ability of these two compounds to inhibit monocyte adhesion and surface expression of endothelial adhesion molecules was evaluated and compared with that of other NO donors. SP/W 5186 and SP/W 3672 inhibited the adhesion of U937 monocytes to cultured human endothelial cells more potently than S-nitrosoglutathione (GSNO) or spermine NONOate, whereas nitroglycerin and isosorbide dinitrate were ineffective at comparable concentrations. A similar rank order of potency was found for the inhibition of expression of the adhesion molecules vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin as well as for major histocompatibility complex class II antigen expression. Estimated IC(50) values for vascular cell adhesion molecule-1 were >400 microM for SP/W 4744 (control for SP/W 3672 lacking the cysteine moiety), 200 microM for GSNO and spermine NONOate, 80 microM for SP/W 3672, and 50 microM for SP/W 5186. Moreover, SP/W 5186 inhibited VCAM-1 mRNA levels more potently than GSNO. This effect was likely to be transcriptional because mRNA degradation was not affected. In conclusion, SP/W 3672 and SP/W 5186 are novel potent inhibitors of endothelial activation, and this effect appears to relate to their ability to liberate NO for prolonged periods of time, either spontaneously or after conversion to active hydrolytic products.
Assuntos
Cisteína/análogos & derivados , Endotélio Vascular/efeitos dos fármacos , Glutationa/análogos & derivados , Doadores de Óxido Nítrico/farmacologia , Adesão Celular/efeitos dos fármacos , Cisteína/farmacocinética , Cisteína/farmacologia , Dipeptídeos/farmacocinética , Dipeptídeos/farmacologia , Interações Medicamentosas , Selectina E/biossíntese , Endotélio Vascular/citologia , Endotélio Vascular/fisiologia , Glutationa/farmacocinética , Glutationa/farmacologia , Antígenos de Histocompatibilidade Classe II/biossíntese , Humanos , Molécula 1 de Adesão Intercelular/biossíntese , Interferon gama/farmacologia , Interleucina-1/antagonistas & inibidores , Interleucina-1/farmacologia , Nitratos/farmacocinética , Nitratos/farmacologia , Doadores de Óxido Nítrico/farmacocinética , Compostos Nitrosos/farmacocinética , Compostos Nitrosos/farmacologia , Pró-Fármacos/farmacocinética , Pró-Fármacos/farmacologia , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , S-Nitrosoglutationa , Relação Estrutura-Atividade , Compostos de Sulfidrila/farmacologia , Transcrição Gênica/efeitos dos fármacos , Molécula 1 de Adesão de Célula Vascular/biossíntese , Molécula 1 de Adesão de Célula Vascular/genéticaRESUMO
Despite its widespread use, diclofenac has gastrointestinal liabilities common to nonsteroidal antiinflammatory drugs (NSAIDs) that might be reduced by concomitant administration of a gastrointestinal cytoprotectant such as nitric oxide (NO). A series of novel diclofenac esters containing a nitrosothiol (-S-NO) moiety as a NO donor functionality has been synthesized and evaluated in vivo for bioavailability, pharmacological activity, and gastric irritation. All S-NO-diclofenac derivatives acted as orally bioavailable prodrugs, producing significant levels of diclofenac in plasma within 15 min after oral administration to mice. At equimolar oral doses, S-NO-diclofenac derivatives (20a-21b) displayed rat antiinflammatory and analgesic activities comparable to those of diclofenac in the carrageenan-induced paw edema test and the mouse phenylbenzoquinone-induced writhing test, respectively. All tested S-NO-diclofenac derivatives (20a-21b) were gastric-sparing in that they elicited markedly fewer stomach lesions as compared to the stomach lesions caused by a high equimolar dose of diclofenac in the rat. Nitrosothiol esters of diclofenac comprise a novel class of NO-donating compounds having therapeutic potential as nonsteroidal antiinflammatory agents with an enhanced gastric safety profile.